๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Hebei
Clinical trial register · China

Clinical Trials in Hebei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hebei

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
NCT07792681Migraine, With or Without Aura
Brise Pharmaceuticals Co., Ltd.
Phase 2/3
2,079
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-15
Not yet open
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07799077Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
32
Hebei
2026-09-01
Not yet open
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
NCT07650825Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
30
Hebei
2026-08-01
Not yet open
Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars
NCT07620769Acne Scars, Acne Scars - Atrophic, Acne Scar, Acne Scarring
CLASSYS Inc.
Not applicable
252
Chengdu, Chongqing, Hebei, Shanghai
2026-06
Not yet open
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
NCT07610434IBS, Diarrhea Predominant
Beijing Hospital of Traditional Chinese Medicine
Phase 3
636
Beijing, Chengdu, Chongqing, Guangzhou, Guizhou, Haozhou, Hebei, Heilongjiang
2026-05-31
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
NCT07262164Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hebei
2026-03-18
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Not yet open
Prevalence and Determinants of Migraine Among Headache Patients
NCT07038499Headache (Migraine)
Universiti Tunku Abdul Rahman
Observational
158
Hebei
2025-06-23
Recruiting
School-Based Intervention to Enhance Resilience and Stress Coping in Rural Chinese Adolescents
NCT07115186Stress, Emotional, Stress-related Mental Disorders
Peking University
Not applicable
850
Hebei
2025-05-12
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
Venetoclax-Decitabine in Untreated Elderly/Unfit AML
NCT07117422AML, Adult
The Second Hospital of Hebei Medical University
Not applicable
39
Hebei
2025-01-17
Recruiting
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
NovaOnco Therapeutics Co., Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
A Prognostic Model for Drug-induced Liver Injury in China
NCT05060289Drug-induced Liver Injury
Beijing Friendship Hospital
Observational
3,000
Beijing, Dalian, Guangxi, Hebei, Jiaozuo, Lanzhou, Qingdao, Qinghai
2022-05-25
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
NCT05129904DPMAS Therapy in Liver Disease Patients
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hebei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Hebei.

How many clinical trials are recruiting in Hebei?

8 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hebei), 18 studies
PhaseStudiesRecruitingShare
Observational5227.8%
Not applicable4322.2%
Phase 14322.2%
Phase 22011.1%
Phase 2/3105.6%
Phase 3105.6%
Phase 4105.6%

Most active sponsors

Lead sponsors with the most studies (Hebei)
Lead sponsorStudiesRecruiting
AstraZeneca10
Beijing Friendship Hospital11
Beijing Hospital of Traditional Chinese Medicine10
Brise Pharmaceuticals Co., Ltd.10
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
CLASSYS Inc.10
Daiichi Sankyo11
Hebei Medical University Fourth Hospital10
Nanfang Hospital, Southern Medical University10
NovaOnco Therapeutics Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.